Emerald Mutual Fund Advisers Trust Has $420,000 Stake in Orthofix Medical Inc. $OFIX

Emerald Mutual Fund Advisers Trust decreased its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 92.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,625 shares of the medical device company’s stock after selling 476,899 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Orthofix Medical were worth $420,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of OFIX. Philosophy Capital Management LLC acquired a new stake in Orthofix Medical in the 1st quarter valued at approximately $6,047,000. Engine Capital Management LP raised its holdings in shares of Orthofix Medical by 8.4% in the first quarter. Engine Capital Management LP now owns 3,741,390 shares of the medical device company’s stock valued at $61,022,000 after purchasing an additional 290,646 shares during the last quarter. Juniper Investment Company LLC raised its holdings in shares of Orthofix Medical by 10.3% in the first quarter. Juniper Investment Company LLC now owns 2,137,374 shares of the medical device company’s stock valued at $34,861,000 after purchasing an additional 200,125 shares during the last quarter. Nuveen LLC acquired a new stake in Orthofix Medical in the 1st quarter valued at $1,445,000. Finally, Jane Street Group LLC acquired a new stake in Orthofix Medical in the 1st quarter valued at $1,076,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Price Performance

NASDAQ:OFIX opened at $15.47 on Friday. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $20.73. The company has a market cap of $610.91 million, a P/E ratio of -4.88 and a beta of 0.89. The firm’s fifty day moving average price is $14.87 and its two-hundred day moving average price is $12.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The company had revenue of $203.12 million during the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Equities analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research report on Wednesday, October 8th. Wall Street Zen raised Orthofix Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Barrington Research reaffirmed an “outperform” rating and set a $17.00 price target on shares of Orthofix Medical in a research report on Thursday, October 23rd. Finally, Stifel Nicolaus assumed coverage on Orthofix Medical in a research report on Tuesday. They set a “buy” rating and a $22.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.